https://doi.org/10.55788/077d0484
This multicentre, prospective, observational study enrolled 152 adult patients (121 men; mean age 35 years) diagnosed with EoE across 8 Italian centres and 1 Israeli centre [1]. Participants received budesonide 1 mg twice daily as induction treatment for at least 12 weeks. Outcomes were evaluated after 12 weeks using the Endoscopic Reference Score (EREFS) for endoscopic appearance, the peak eosinophilic infiltration for histological assessment, and the Dysphagia Symptom Questionnaire (DSQ) and Health-Related Quality of Life (HRQoL) questionnaire for clinical response. The primary endpoints were endoscopic and histological remission, along with improvements in dysphagia symptoms and quality-of-life.
The results shared by Prof. Edoardo Savarino (University of Padua, Italy) showed that 54% of the participants achieved endoscopic remission, with the mean EREFS score decreasing from 3.1 to 1.3 (P<0.001). The histological remission was observed in 91% of the participants, with a mean peak eosinophil count dropping from 33.3 eosinophils/high power field at baseline to 3.1 at week 12 (P<0.001).
Regarding the dysphagia symptom, the mean DSQ score significantly decreased from 20.3 to 4.8 (P=0.001), while the quality-of-life improved, with mean HRQoL scores increasing from 119.6 to 140 (P=0.02).
Side effects were reported in 14 out of 151 participants (9.2%), with 4 requiring treatment discontinuation.
This study confirms budesonide's efficacy in inducing remission in patients with EoE, significantly improving clinical, endoscopic, and histological outcomes. The safety profile was favourable, with minimal treatment discontinuations.
- Savarino EV, et al. Real-world evidence of the effectiveness and safety of orodispersible budesonide tablet for the treatment of eosinophilic esophagitis: a multicentre prospective study evaluating the induction period. Sa1293, DDW 2024, 18–21 May, Washington DC, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Dupilumab shows promising results in treating paediatric eosinophilic oesophagitis Next Article
Mepolizumab improves the histologic severity of eosinophilic oesophagitis »
« Dupilumab shows promising results in treating paediatric eosinophilic oesophagitis Next Article
Mepolizumab improves the histologic severity of eosinophilic oesophagitis »
Table of Contents: DDW 2024
Featured articles
PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise
Eosinophilic Oesophagitis Treatments and Outcomes
Mepolizumab improves the histologic severity of eosinophilic oesophagitis
Budesonide demonstrates efficacy in eosinophilic oesophagitis
Dupilumab shows promising results in treating paediatric eosinophilic oesophagitis
Quality-of-life assessment in children with eosinophilic oesophagitis
Gut-Brain Axis and Neurological Disorders
Gut permeability and neuroinflammation linked in Parkinson’s disease
Cardiovascular and Metabolic Health Innovations
Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity
Inflammatory Bowel Disease Therapies
GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease
QUASAR maintenance study: Guselkumab effective and safe for UC
VEDOKIDS: Vedolizumab maintains remission in patients with paediatric IBD
ADMIRE-CD II: Darvadstrocel does not meet primary endpoint in complex Crohn’s perianal fistulas
Advances in Endoscopy and Screening Techniques
PREEMPT CRC: Blood-based screening test for colorectal cancer shows promise
New cable-transmission capsule endoscopy shows high accuracy in detecting upper GI lesions
Liver and Biliary Tract Diseases Updates
Superior OS with atezolizumab plus bevacizumab versus lenvatinib in unresectable HCC
Nutritional consultation boosts nutritional status in patients with alcohol-associated hepatitis
REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH
Acalculous cholecystitis as a risk factor for gallbladder perforation: insights from a 10-year retrospective study
Other Gastrointestinal Diseases
STARS: Apraglutide shows efficacy in short bowel syndrome with intestinal failure
COX-2 inhibitors show promise in reducing severity of acute pancreatitis
Hormone-containing therapies may increase the risk of IBS and functional dyspepsia
Related Articles
October 23, 2019
Human milk oligosaccharides improve IBS symptoms
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com